CAR-T cell therapy for lung cancer: Potential and perspective.
CAR-T cell therapy for lung cancer: Potential and perspective.
复制标题
DOI：
10.1111/1759-7714.14375
复制
发表时间：
2022-04
期刊：
影响因子：
2.9
通讯作者：
Huang Y
中科院分区：
文献类型：
--
作者：
Chen L;Chen F;Li J;Pu Y;Yang C;Wang Y;Lei Y;Huang Y
肺癌是世界上发病率和死亡率最高的癌症。在目前的免疫治疗时代，包括单抗靶向药物在内的越来越多的免疫治疗剂已被用于恶性肿瘤的临床治疗，但仍有许多局限性。嵌合抗原受体修饰T细胞(CAR-T细胞)是一种新的过继免疫治疗策略，不仅成功地用于治疗血液系统肿瘤，而且为包括肺癌在内的实体瘤的免疫治疗开辟了新的途径。然而，利用基因工程的CAR-T细胞靶向肺癌特异性抗原存在肿瘤特异性抗原缺乏、肿瘤微环境免疫抑制、CAR-T细胞在肿瘤组织中的低水平浸润以及非靶点效应等问题。同时，由于肿瘤溶解综合征、神经毒性综合征和细胞因子释放综合征等诸多挑战，CAR-T细胞的临床应用仍然受到限制。本文概述了CAR-T细胞的基本结构和生成特点，总结了CAR-T细胞治疗肺癌临床试验中常见的肿瘤相关抗原，并指出了当前面临的挑战和新的策略，旨在为肺癌CAR-T细胞治疗的临床前实验和临床试验提供新的思路和方法。CAR-T细胞免疫疗法的临床应用过程。CAR-T的临床过程如下：T淋巴细胞采集；CAR-T细胞制造；CAR-T细胞体外扩增和筛选；CAR-T细胞回输给患者；CAR-T细胞被运送到肿瘤部位并在肿瘤微环境中发挥作用。
Lung cancer is the highest incidence and mortality of all cancers around the world. In the present immunotherapy era, an increasing number of immunotherapeutic agents including monoclonal antibody‐targeted drugs have been used in the clinical treatment of malignancy, but it still has many limitations. Chimeric antigen receptor‐modified T (CAR‐T) cells, a novel adoptive immunotherapy strategy, have not only been used successfully against hematological tumors, but have also opened up new avenues for immunotherapy of solid tumors, including lung cancer. However, targeting lung cancer‐specific antigens using engineered CAR‐T cells is complicated by the lack of proper tumor‐specific antigens, an immunosuppressive tumor microenvironment, a low level of CAR‐T cell infiltration into tumor tissues, along with off‐target effect, etc. Simultaneously, the clinical application of CAR‐T cells remains limited because of many challenges such as tumor lysis syndrome, neurotoxicity syndrome, and cytokine release syndrome. In this review, we outline the basic structure and generation characteristic of CAR‐T cells and summarize the common tumor‐associated antigens in clinical trials of CAR‐T cell therapy for lung cancer, and point out the current challenges and new strategies, aiming to provide new ideas and approaches for the pre‐clinical experiments and clinical trials of CAR‐T cell therapy in lung cancer. The clinical application process of CAR‐T cell immunotherapy. The clinical process of CAR T is as listed: T lymphocyte collection; CAR T‐cell manufacturing; CAR T‐cell amplification and screening in vitro; CAR‐T cells are infused back into patients; CAR‐T cells are transported to the tumor site and perform their function in the tumor microenvironment.
登录
查看更多内容
影响因子：
1.3
作者：
Dong, Yanjun;Zheng, Xianjie;Zhang, Shuanglin
通讯作者：
Zhang, Shuanglin
DOI：
10.1016/s0140-6736(17)33326-3
发表时间：
2018-03-17
期刊：
Lancet (London, England)
影响因子：
--
作者：
Allemani C;Matsuda T;Di Carlo V;Harewood R;Matz M;Nikšić M;Bonaventure A;Valkov M;Johnson CJ;Estève J;Ogunbiyi OJ;Azevedo E Silva G;Chen WQ;Eser S;Engholm G;Stiller CA;Monnereau A;Woods RR;Visser O;Lim GH;Aitken J;Weir HK;Coleman MP;CONCORD Working Group
通讯作者：
CONCORD Working Group
DOI：
10.1038/mto.2016.11
发表时间：
2016
期刊：
Molecular therapy oncolytics
影响因子：
--
作者：
通讯作者：
--
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
11.5
作者：
Gulati, Pratiksha;Ruhl, Julia;Petrausch, Ulf
通讯作者：
Petrausch, Ulf